Bristol-Myers Squibb to Post Select Investigational Compound Data Updates on Company Website

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will begin posting updates about select Phase 1 and 2 investigational compounds on the company website at www.bms.com/research/investigational. The updates will communicate an overview of new data presented at medical meetings or data published in scientific journals. The first update will be posted on Saturday, April 17, 2010.

Media and investors interested in receiving notifications when investigational compound updates are posted may subscribe to Bristol-Myers Squibb’s “Investigational Compound News” RSS feed at www.bms.com/news/pages/rss_alerts.aspx.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Sonia Choi, 609-252-5132
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China.

Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint.

Scientists at the Broad Institute and the Dana-Farber Cancer Institute identified 49 existing drugs they believe could be repurposed to treat cancer.